Stay updated on Immunotherapy for Metastatic Cancers with CDK12 Mutations Clinical Trial
Sign up to get notified when there's something new on the Immunotherapy for Metastatic Cancers with CDK12 Mutations Clinical Trial page.

Latest updates to the Immunotherapy for Metastatic Cancers with CDK12 Mutations Clinical Trial page
- ChecktodayChange DetectedA site-wide notice says NIH websites are transitioning terminology from “Artificial Intelligence” to “Super Intelligence” and links to updates and FAQs.SummaryDifference1%

- Check7 days agoChange DetectedThe footer’s site revision identifier changed from v3.7.1 to v3.7.2; the page continues to display a 403 error.SummaryDifference0.2%

- Check14 days agoChange DetectedThe site footer revision changes from v3.7.0 to v3.7.1, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check35 days agoChange DetectedThe page now displays a 403 Forbidden error instead of the study details. This indicates restricted access to the record and replaces the usual content with an error screen.SummaryDifference19%

- Check56 days agoChange DetectedThe revision tag on the page updates from v3.6.5 to v3.6.6, indicating a new build. No study details, eligibility criteria, or results content were changed.SummaryDifference0.1%

- Check77 days agoChange DetectedThe page's revision stamp was updated from v3.6.4 to v3.6.5, indicating a frontend update to this ClinicalTrials.gov page.SummaryDifference0.0%

Stay in the know with updates to Immunotherapy for Metastatic Cancers with CDK12 Mutations Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Immunotherapy for Metastatic Cancers with CDK12 Mutations Clinical Trial page.